A randomized, double-blind, placebo-controlled Phase III study to investigate the efficacy and safety of progesterone in patients with severe traumatic brain injury.
Sponsored by BHR Pharma, LLC. The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery. Identifier: